Clinical Trial Update: KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating KC1036 in combination with a PD-1 antibody and platinum-based chemotherapy as first-line treatment for advanced esophageal squ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• KC1036
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Beijing Konruns Pharmaceutical Co., Ltd. | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Status: RECRUITING